Details : NLS-2 (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Product Name : Quilience
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 07, 2023
Details : Quviviq (daridorexant) is a dual orexin receptor antagonist. Currently, it is being evaluated in the Phase III clinical trial studies for treatment of adult patients with insomnia.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia to Present New Phase 3 Data on Daridorexant in Insomnia at Sleep 2021
Details : The placebo-controlled studies investigated the effects of three doses of daridorexant (10 mg, 25 mg, and 50 mg) on sleep and daytime functioning parameters, objectively in a sleep lab by polysomnography and subjectively with a daily patient diary at hom...
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 06, 2021
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quviviq (daridorexant) is a dual orexin receptor antagonist. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of adult patients with insomnia.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $588.0 million
Deal Type : Financing
Idorsia Successfully Completes Capital Increase with Gross Proceeds of CHF 535.5 Million
Details : The increased liquidity will be used to prepare for the launch of daridorexant and further fund Idorsia’s diversified pipeline.
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $588.0 million
Deal Type : Financing
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daridorexant Phase 3 Results In Insomnia to be Presented at Sleep 2020
Details : Results from the first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia, are to be presented at SLEEP 2020.
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 13, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $632.0 million
Deal Type : Financing
Details : The proceeds from the offering will be used to support the regulatory filing and, if approved, commercial launch of daridorexant and to fund the further development of its diversified pipeline.
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $632.0 million
Deal Type : Financing
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia Japan Confirms Daridorexant Dose Response in Japanese Patients with Insomnia
Details : Treatment with daridorexant in 47 adult patients (ranging from 16 to 64 years) showed a significant dose-dependent decrease in WASO at Day 1 & 2 (average decrease of wake time after sleep onset from baseline on the 2 nights of treatment.
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Second PhIII Study for Idorsia's Sleep Drug Returns Positive Results
Details : The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime functioning, with patients reporting no morning sleepine...
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 07, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia's Rival to Merck's Insomnia Drug Clears Phase 3 Test
Details : The study demonstrated efficacy of treatment with daridorexant on objective and subjective sleep parameters and daytime performance with no residual effect in the morning.
Product Name : ACT-541468
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable